Therapeutic ultrasound is an active medical device technology that delivers acoustic energy into body tissue to produce heating, mechanical, or ablative effects for treatment rather than imaging. Applications range from ultrasonic physiotherapy for musculoskeletal conditions to high-intensity focused ultrasound (HIFU) for non-invasive tumor ablation and aesthetic procedures.

---

What is Therapeutic Ultrasound?

Therapeutic ultrasound describes any medical device that uses ultrasonic energy (typically 20 kHz and above) to induce a physical or biological effect in tissue, rather than to generate an image. The category covers ultrasonic diathermy devices used in rehabilitation, focused ultrasound systems for aesthetic tightening and lipolysis, high-intensity focused ultrasound (HIFU) systems for tumor ablation, and lithotripters for breaking up kidney stones.

Unlike diagnostic imaging systems governed by IEC 60601-2-37, therapeutic ultrasound devices are designed to deposit meaningful acoustic power into tissue. That single design intent, energy delivery rather than energy reception, drives most of the safety engineering, regulatory classification, and clinical evaluation work that follows.

---

Why Therapeutic Ultrasound matters in medical device development

Every therapeutic ultrasound device is an active energy-emitting product, which places it in a higher-risk regulatory bucket from day one. Under EU MDR 2017/745, ultrasonic physiotherapy equipment is typically Class IIa under Rule 9, while HIFU systems for lipolysis or ablation move up to Class IIb or III depending on indication and mechanism. In the United States, ultrasonic diathermy devices sit under 21 CFR 890.5300(a) as Class II with product codes IMI and PFW, while aesthetic-focused ultrasound falls under 21 CFR 878.4590, and non-thermal mechanical tissue ablation systems under 21 CFR 878.4405.

Getting classification, acoustic output limits, and clinical evidence wrong can delay a submission by many months. Because output power directly correlates with patient harm potential, notified bodies and FDA reviewers scrutinize acoustic measurements, transducer characterization, and cooling behavior more closely than for most Class II devices.

---

How Therapeutic Ultrasound works

At a system level, a therapeutic ultrasound device converts electrical energy into acoustic energy at a defined frequency, focuses or shapes that energy, and delivers it to a treatment site through a coupling medium. Core components include:

• A piezoelectric transducer that converts electrical excitation into mechanical vibration, sized and shaped for the intended tissue depth and focal geometry.
• An RF signal generator and matching network that drive the transducer at its resonant frequency with controlled duty cycle, pulse duration, and duty ratio.
• A cooling and temperature-monitoring subsystem to manage transducer self-heating and, in HIFU, tissue temperature rise.
• A user interface with dose parameters, treatment timers, and interlocks aligned with usability requirements in IEC 62366-1.
• For image-guided systems, an integrated diagnostic ultrasound or MRI targeting module is used only for planning and verification.

Governing standards include IEC 60601-1 (Edition 3.2) for general basic safety and essential performance, IEC 60601-2-5 for ultrasonic physiotherapy equipment, and IEC 60601-2-62 for HITU (high-intensity therapeutic ultrasound) systems. Acoustic characterization uses IEC 62555 for output power measurement and IEC/TS 62556 for HITU field specification. Risk management follows ISO 14971:2019 and, for any embedded software, IEC 62304 lifecycle requirements apply.

---

Common challenges and best practices

Teams building therapeutic ultrasound devices tend to hit a predictable set of engineering and compliance issues.

Acoustic output verification is the first. Regulators want traceable measurements of temporal-average intensity, peak rarefactional pressure, and derated power at declared settings. Building a repeatable acoustic test bench with a calibrated hydrophone or radiation force balance early avoids painful re-testing after design freeze.

Thermal safety is the second. Even at physiotherapy power levels, transducer face temperature and treated tissue temperature can drift outside safe limits during long duty cycles. Thermal modeling and in-situ temperature validation should feed the ISO 14971 risk file, not be added retroactively.

Usability is the third, and often underestimated. IEC 62366-1 requires evidence that clinicians can select correct dose parameters without confusing intensity, duty cycle, and treatment time. A clean information architecture on the UI reduces both use errors and 510(k) review questions.

Cybersecurity applies to any connected therapeutic ultrasound system. IEC 81001-5-1 defines the health software security life cycle, and the FDA now expects an SBOM and threat model with premarket submissions.

---

How SJML helps with Therapeutic Ultrasound

SJML has therapeutic ultrasound as a named platform capability inside its technology portfolio, alongside radiofrequency, electrotherapy, and microneedling. Engagements can begin at concept, feasibility, or design transfer, and cover the full electromechanical stack: transducer integration, RF driver electronics, embedded firmware, user interface, and mechanical enclosure design. QARA support runs in parallel, including risk management to ISO 14971, IEC 60601 series testing planning, IEC 62366-1 usability files, and international registration strategy for FDA 510(k) and EU MDR routes. Manufacturing scale-up uses ISO Class 7 and 8 cleanrooms, medical PCBA, and process validation (IQ/OQ/PQ).

Talk to SJML’s engineering team →

---

Frequently asked questions

---

Related terms

• High Intensity Focused Ultrasound (HIFU)
• IEC 60601-1
• Ultrasonic Diathermy
• Usability Engineering (IEC 62366-1)
• Acoustic Output Testing